Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
| ▸ | NPY2R | P49146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861822 | 0.71 | CYP1A2 (0.51) | KDM4EALDH1A1GAA | |
| SCHEMBL3857762 | 0.71 | HDAC6 (0.44) | LMNASMN1; SMN2KMT2AKDM4EATM | |
| SCHEMBL3865365 | 0.67 | PTGDR2 (0.41) | ALDH1A1 | |
| SCHEMBL19132554 | 0.61 | ABCB1 (0.46) | LMNAKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL3857059 | 0.59 | CYP1A2 (0.49) | KDM4EALDH1A1GAA | |
| SCHEMBL19471046 | 0.58 | KEAP1 (0.34) | KMT2A | |
| SCHEMBL8531499 | 0.58 | SIRT1 (0.56) | SMN1; SMN2KDM4ERAB9AALDH1A1 | |
| SCHEMBL5625371 | 0.57 | AKR1C4 (0.31) | — | |
| SCHEMBL22528275 | 0.57 | HTR5A (0.45) | — | |
| SCHEMBL19471000 | 0.56 | DRD1 (0.39) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592454-B2 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | HTR1A, HTR7, HTR1D | LMNA 3302/4885TP53 3748/4885SMN1; SMN2 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.